title: [Hepatocellular carcinoma: what's new?].
authors.affiliation: I. Medizinische Klinik und Poliklinik, Universitätsmedizin, Mainz. teufel@uni-mainz.de
authors.forename: A
authors.initials: A
authors.lastname: Teufel
authors.forename: J U
authors.initials: JU
authors.lastname: Marquardt
authors.forename: P R
authors.initials: PR
authors.lastname: Galle
authors.forename: M
authors.initials: M
authors.lastname: Wörns
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D003952:Diagnostic Imaging; D020869:Gene Expression Profiling; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D016031:Liver Transplantation; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011379:Prognosis; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use; D000077157:Sorafenib; D015996:Survival Rate; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D014408:Biomarkers, Tumor; D007166:Immunosuppressive Agents; D010671:Phenylurea Compounds; D011725:Pyridines; D000509:alpha-Fetoproteins; D009536:Niacinamide; D000077157:Sorafenib; D020123:Sirolimus